182 related articles for article (PubMed ID: 21142807)
1. Patupilone in cancer treatment.
Bystricky B; Chau I
Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
[TBL] [Abstract][Full Text] [Related]
2. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
Cortes J; Baselga J
Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
4. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
5. The epothilones: how pharmacology relates to clinical utility.
Michaud LB
Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
[TBL] [Abstract][Full Text] [Related]
6. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
8. Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Cigler T; Vahdat L
Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S166-70. PubMed ID: 19158037
[TBL] [Abstract][Full Text] [Related]
9. Epothilone D (Kosan/Roche).
Kolman A
Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical applications of epothilones: a review of phase II studies.
Larkin JM; Kaye SB
Ann Oncol; 2007 Jul; 18 Suppl 5():v28-34. PubMed ID: 17656559
[TBL] [Abstract][Full Text] [Related]
11. Epothilones: clinical update and future directions.
Donovan D; Vahdat LT
Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
[TBL] [Abstract][Full Text] [Related]
12. EPO-906 (Novartis).
Galmarini CM; Dumontet C
IDrugs; 2003 Dec; 6(12):1182-7. PubMed ID: 14666430
[TBL] [Abstract][Full Text] [Related]
13. The epothilones: translating from the laboratory to the clinic.
Lee JJ; Swain SM
Clin Cancer Res; 2008 Mar; 14(6):1618-24. PubMed ID: 18347162
[TBL] [Abstract][Full Text] [Related]
14. Activity of epothilones.
Kolman A
Curr Opin Investig Drugs; 2005 Jun; 6(6):616-22. PubMed ID: 15988913
[TBL] [Abstract][Full Text] [Related]
15. Current perspectives of epothilones in breast cancer.
Cardoso F; de Azambuja E; Lago LD
Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
[TBL] [Abstract][Full Text] [Related]
16. Interaction of epothilone B (patupilone) with microtubules as detected by two-dimensional solid-state NMR spectroscopy.
Kumar A; Heise H; Blommers MJ; Krastel P; Schmitt E; Petersen F; Jeganathan S; Mandelkow EM; Carlomagno T; Griesinger C; Baldus M
Angew Chem Int Ed Engl; 2010 Oct; 49(41):7504-7. PubMed ID: 20809556
[No Abstract] [Full Text] [Related]
17. [Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Villanueva C; Dufresne A; Pivot X; Viel E
Bull Cancer; 2008 Feb; 95(2):197-204. PubMed ID: 18304905
[TBL] [Abstract][Full Text] [Related]
18. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
Morris PG; Fornier MN
Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
[TBL] [Abstract][Full Text] [Related]
19. Epothilones in breast cancer: current status and future directions.
Atzori F; Fornier M
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1299-311. PubMed ID: 18699766
[TBL] [Abstract][Full Text] [Related]
20. Epothilones in the treatment of cancer.
Larkin JM; Kaye SB
Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]